^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CD36 stimulant

    Related drugs:
    6ms
    Phase 1 dose expansion and biomarker study assessing first-in-class tumor microenvironment modulator VT1021 in patients with advanced solid tumors. (PubMed, Commun Med (Lond))
    VT1021 is safe and well-tolerated in patients with solid tumors in a phase I expansion study. VT1021 has advanced to a phase II/III clinical study in glioblastoma (NCT03970447).
    P1 data • Journal • Metastases
    |
    THBS1 (Thrombospondin 1)
    |
    VT1021